目的：找出我国治疗用重组蛋白多肽类产品存在的不足，明确未来努力方向。方法：基于我国已上市治疗用重组蛋白多肽类产品批准数据进行统计分析和对比分析。结果：对我国已上市的重组蛋白多肽类产品的基本情况、技术代次、治疗领域等进行了回顾梳理。结论：我国重组蛋白多肽类药物在新一代产品的开发上，由于企业创新不足及技术落后，与国际先进水平的差距近年来在进一步加大。
Objective:To find out the shortcomings of recombinant protein or peptide products for therapeutic use in China and determine the future direction. Methods:Based on the approval data of recombinant protein or peptide products in China, the statistical analysis and comparative analysis were conducted. Results:The basic situation, technical generation and therapeutic field of the recombinant protein or peptide drugs listed in China were reviewed and analyzed. Conclusion:Due to the lack of innovation and backward technology in the development of new generation products, the gap between recombinant protein or peptide drugs and the international advanced level has been further widened in recent years.
[1] 曲耀成,姚雪静. 重组蛋白类药物蛋白含量测定方法研究进展[J]. 药学研究,2018,37(3):174-177.
[2] 谢华玲,陈芳,Cynthia Liu,等. 全球生物制药领域研发态势分析[J]. 中国生物工程杂志,2019,39(5):1-10.
[3] 徐欢,周美玲,葛琳,等. 人血清白蛋白在蛋白多肽类药物长效化中的应用[J]. 中国生物工程杂志, 2019,39(1):82-89.
[4] 刘志磊,张彦彦,李小芳. 我国生物制品的注册历程分析[J]. 中国新药杂志,2018,27(21):2584-2587.
[5] 慢病管理网. 新版糖尿病地图发布:中国糖尿病人数1.14亿,居全球首位[EB/OL].(2017-11-29)[2019-04-24]. https://mp.weixin.qq.com/s/24KVngcQG21s1QeOYwuCBQ.
[6] FDA. Purple Book[EB/OL].(2018-12)[2019-04-24]. https://www.fda.gov/drugs/therapeutic-biologicsapplications-bla/purple-book-lists-licensedbiological-products-reference-product-exclusivityand-biosimilarity-or.
[7] 王海荣. 不同胰岛素给药方式治疗糖尿病的临床研究[J]. 全科口腔医学电子杂志,2019,6(19):197.
